Yamamoto T, Yasuda J, Kanao M, Okada H
Department of Obstetrics and Gynecology, Kyoto Prefectural University of Medicine.
Jpn J Antibiot. 1987 May;40(5):1074-83.
Fundamental and clinical studies on cefuzonam (CZON, L-105), a new oxime type cephalosporin, were performed and the results obtained are summarized below: 1. Concentrations of CZON were determined in serum, internal genital organs and retroperitoneal fluid after a single intravenous administration of 1 g dose. The peripheral serum level of CZON was 74.0 micrograms/ml at 15 minutes after the administration. A sufficient transfer of CZON into internal genital organs and retroperitoneal fluid was demonstrated. 2. In clinical trial, CZON was given to 11 cases with obstetrical and gynecological infections. Efficacies were evaluated as good in 9 cases and poor in 2 cases. No side effects were observed in any of the cases treated with CZON. In laboratory examinations, transient elevation of serum GOT, GPT and alkaline phosphatase was noted in 1 case.
对新型肟型头孢菌素头孢唑南（CZON，L - 105）进行了基础和临床研究，所得结果总结如下：1. 单次静脉注射1g剂量后，测定血清、内生殖器器官和腹膜后液中头孢唑南的浓度。给药后15分钟时，头孢唑南外周血清水平为74.0微克/毫升。证明头孢唑南能充分转移至内生殖器器官和腹膜后液中。2. 在临床试验中，对11例妇产科感染患者给予头孢唑南。疗效评估为9例良好，2例较差。在接受头孢唑南治疗的任何病例中均未观察到副作用。在实验室检查中，1例患者血清谷草转氨酶、谷丙转氨酶和碱性磷酸酶出现短暂升高。
